Truist Financial Corp Sells 2,818 Shares of Charles River Laboratories International, Inc. $CRL

Truist Financial Corp decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 38.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,438 shares of the medical research company’s stock after selling 2,818 shares during the period. Truist Financial Corp’s holdings in Charles River Laboratories International were worth $694,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of CRL. Neo Ivy Capital Management purchased a new stake in shares of Charles River Laboratories International during the second quarter valued at $29,000. Geneos Wealth Management Inc. lifted its stake in Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 145 shares during the period. Allworth Financial LP boosted its holdings in shares of Charles River Laboratories International by 172.7% during the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 190 shares during the last quarter. SJS Investment Consulting Inc. bought a new stake in shares of Charles River Laboratories International in the third quarter worth approximately $48,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Charles River Laboratories International in the second quarter worth approximately $56,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Bank of America upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective on the stock in a research report on Monday, December 15th. Barclays increased their price target on Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Citigroup raised their price target on Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Argus set a $200.00 price objective on Charles River Laboratories International in a research report on Monday, November 17th. Finally, Evercore increased their target price on Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Ten analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Moderate Buy” and a consensus target price of $209.46.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock opened at $181.16 on Wednesday. The stock has a market cap of $8.92 billion, a P/E ratio of -116.13, a P/E/G ratio of 5.57 and a beta of 1.63. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37. The stock’s fifty day moving average is $204.63 and its 200 day moving average is $180.05. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $228.88.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.